Melasma: Causes, Risk Factors, and Treatment

You've been diligent about sunscreen, you've avoided harsh products, and yet the dark patches on your face keep deepening. You're told it's "just cosmetic," but the reflection in the mirror tells a different story. Melasma doesn't follow the rules of typical hyperpigmentation, and understanding why it appears, persists, and resists treatment requires looking beyond the surface.

Key Takeaways

• Melasma is driven by melanocyte hyperactivity, not dirt or surface damage.
• Hormonal fluctuations from pregnancy, birth control, or menopause are primary triggers.
• UV and visible light exposure activate melanin production even through sunscreen.
• Melasma is not dangerous or cancerous but signals deeper hormonal patterns.
• The condition reflects systemic factors including inflammation and gut-skin axis dysfunction.
• Treatment resistance is common because melasma involves vascular and immune changes.
• Individual variation in skin type, hormones, and genetics determines severity and response.

What Melasma Actually Is and Where It Starts

Melasma is a chronic pigmentation disorder characterized by symmetrical brown or gray-brown patches, most commonly on the face. Unlike post-inflammatory hyperpigmentation that follows injury or inflammation, melasma arises from melanocyte hyperactivity triggered by hormonal, environmental, and genetic factors. The melanocytes in affected areas produce excess melanin in response to stimuli that wouldn't normally cause pigmentation in unaffected skin.

The condition most often appears on the cheeks, forehead, upper lip, and chin, though melasma on arms and neck can also occur, particularly with chronic sun exposure. The patches are typically bilateral and symmetrical, reflecting the systemic nature of the triggers rather than localized skin trauma.

Histologically, melasma involves several key features:

• Increased melanin in the epidermis, dermis, or both layers of skin.
• Elevated vascularity that delivers nutrients and signaling molecules to hyperactive melanocytes.
• Mast cell infiltration that contributes to inflammatory signaling and pigment production.
• Altered immune signaling that creates a self-reinforcing cycle of pigmentation.

This is not simply a cosmetic issue of "too much pigment." The complex interplay of melanocyte activation, vascular changes, and immune signaling makes melasma notoriously difficult to treat and prone to recurrence.

How Hormones Drive Melasma Through Estrogen and Progesterone Pathways

Melasma is fundamentally a hormonally mediated condition. Estrogen and progesterone, which surge during pregnancy and fluctuate with oral contraceptives and hormone replacement therapy, directly stimulate melanocytes through receptor-mediated pathways. These hormones upregulate melanin synthesis by increasing the activity of tyrosinase, the rate-limiting enzyme in melanin production. This is why melasma is sometimes called the "mask of pregnancy," affecting up to 50% of pregnant women, particularly in the third trimester when hormone levels peak.

Birth control pills, hormone therapy, and even the hormonal shifts of perimenopause and menopause can activate or worsen the condition. Melasma disproportionately affects women of reproductive age, though men can develop it, typically linked to UV exposure and genetic predisposition rather than hormonal surges. The hormonal connection also explains why melasma often improves postpartum or after discontinuing hormonal contraceptives, though it frequently recurs with subsequent pregnancies or hormone use.

Beyond direct melanocyte stimulation, estrogen and progesterone influence skin barrier function, immune tone, and vascular permeability. Elevated estrogen increases vascular endothelial growth factor (VEGF), promoting angiogenesis in affected skin. This increased vascularity actively contributes to pigmentation by delivering more nutrients and signaling molecules to hyperactive melanocytes, creating a self-reinforcing cycle that standard topical treatments struggle to interrupt.

What Triggers Melasma Flares and Determines Severity

UV and visible light exposure

Ultraviolet radiation is the most potent environmental trigger for melasma. UV exposure causes lipid peroxidation in cellular membranes, generating reactive oxygen species (ROS) that stimulate melanocytes to produce excess melanin. Even brief, incidental sun exposure can activate dormant melasma or darken existing patches. Critically, visible light, particularly blue light, also triggers melanogenesis in melasma-prone skin. This means that even broad-spectrum sunscreens, which block UV but not visible light, may not fully protect against progression.

Hormonal fluctuations

Beyond pregnancy and contraceptives, any hormonal shift can influence melasma. Thyroid dysfunction, polycystic ovary syndrome (PCOS), and perimenopause all alter the hormonal milieu in ways that can trigger or worsen pigmentation. Elevated androgens, common in PCOS, increase sebum production and may indirectly affect melanocyte activity. Cortisol, the stress hormone, also plays a role. Chronic stress activates the hypothalamic-pituitary-adrenal (HPA) axis, increasing cortisol levels that impair skin barrier function and amplify inflammatory signaling.

Skin barrier disruption and inflammation

Harsh skincare products, chemical peels, and aggressive exfoliation can worsen melasma by disrupting the skin barrier and triggering post-inflammatory hyperpigmentation. Inflammation activates mast cells and increases cytokine release, which in turn stimulates melanocytes. This is why melasma often worsens after cosmetic procedures intended to improve it. Heat exposure, including from saunas, hot yoga, and even cooking over a stove, can also trigger flares by increasing local blood flow and inflammatory mediators.

Gut-skin axis and systemic inflammation

Emerging research links melasma to gut microbiome composition and systemic inflammation. Dysbiosis, or imbalance in gut bacteria, can increase intestinal permeability, allowing bacterial endotoxins to enter circulation and drive systemic inflammation. This low-grade inflammatory state may amplify melanocyte activity and impair the skin's ability to regulate pigmentation. Studies have found differences in gut microbiome diversity between individuals with and without melasma, suggesting that the gut-skin axis plays a role in both susceptibility and severity.

Why the Same Condition Looks Different in Different People

Melasma presents with significant individual variation in pattern, depth, and treatment response. Skin phototype is a major determinant. Individuals with Fitzpatrick skin types III to VI, common in Hispanic, Asian, Middle Eastern, and African populations, are at higher risk due to greater baseline melanocyte activity and melanin content. However, lighter skin types are not immune, particularly with hormonal triggers or intense UV exposure.

Genetic factors also play a role:

• Family history of melasma increases risk through inherited melanocyte sensitivity patterns.
• Gene variants affecting melanin synthesis determine baseline pigmentation capacity and response to triggers.
• Hormone receptor sensitivity variations influence how strongly melanocytes respond to estrogen and progesterone fluctuations.
• Filaggrin gene mutations impair skin barrier function, increasing sensitivity to environmental triggers.
• Antioxidant capacity genes affect the skin's ability to neutralize reactive oxygen species from UV exposure.

The depth of pigmentation matters clinically. Epidermal melasma, where melanin is confined to the upper layers of skin, responds better to topical treatments than dermal melasma, where pigment has deposited deeper. Mixed-type melasma, involving both epidermal and dermal pigmentation, is the most common and the most challenging to treat. Wood's lamp examination can help differentiate these types, though the distinction isn't always clear-cut.

Hormonal baseline and fluctuation patterns also vary. Women with higher baseline estrogen levels, those who experience dramatic hormonal swings during their menstrual cycle, and individuals with thyroid dysfunction or PCOS may experience more severe or treatment-resistant melasma. Prior use of hormonal contraceptives, particularly those with higher estrogen content, can prime the skin for melasma development even after discontinuation.

When Skin Symptoms Point to Systemic Patterns

While is melasma dangerous is a common concern, the condition is not cancerous or life-threatening. However, persistent or treatment-resistant cases warrant investigation of underlying systemic factors. Melasma can be a visible signal of hormonal imbalance, metabolic dysfunction, or chronic inflammation that deserves attention beyond cosmetic concerns.

Thyroid dysfunction, particularly hypothyroidism, is associated with melasma. Thyroid hormones regulate skin cell turnover, barrier function, and melanocyte activity. When thyroid function is suboptimal, skin becomes more vulnerable to pigmentation disorders. Women with melasma who also experience fatigue, weight changes, or menstrual irregularities should consider thyroid testing, including TSH, free T3, free T4, and thyroid antibodies.

Polycystic ovary syndrome (PCOS) is another common association. Elevated androgens, insulin resistance, and chronic low-grade inflammation in PCOS create a hormonal environment that favors melasma development. Women with melasma accompanied by irregular periods, acne, or hirsutism may benefit from evaluation for PCOS, including fasting insulin, glucose, and androgen levels.

Liver function and detoxification capacity also matter. Melasma has been observed more frequently in individuals with impaired liver function or vitamin B12 deficiency. The liver metabolizes estrogen, and when detoxification pathways are sluggish, estrogen can accumulate, amplifying its effects on melanocytes. Elevated liver enzymes, low B12, or low folate may indicate that melasma is part of a broader metabolic picture.

Chronic inflammation, whether from gut dysbiosis, autoimmune conditions, or metabolic syndrome, can drive melasma by increasing circulating inflammatory cytokines that stimulate melanocyte activity. High-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation, may be elevated in individuals with persistent melasma. Addressing the inflammatory root, rather than just the pigmentation, may improve outcomes. It's worth noting that melasma fungus brown spots on skin is a misconception, as melasma is not caused by fungal infection but rather by the hormonal and inflammatory mechanisms described above.

What Biomarkers Reveal When Topicals Are Not Enough

When melasma persists despite sun protection and topical treatments, testing can uncover the internal drivers. A thorough hormonal panel, including estradiol, progesterone, testosterone, DHEA-S, and SHBG, can reveal imbalances that fuel melanocyte hyperactivity. Elevated estrogen relative to progesterone, or high androgens in the context of PCOS, may explain why melasma won't resolve.

Thyroid function testing, including TSH, free T3, free T4, and thyroid peroxidase antibodies, is essential for anyone with melasma and symptoms of thyroid dysfunction. Subclinical hypothyroidism, where TSH is elevated but thyroid hormones remain in the normal range, can still impair skin health and pigmentation regulation.

Additional biomarkers provide insight into metabolic and inflammatory drivers:

• Fasting insulin, glucose, and HbA1c identify insulin resistance common in PCOS and metabolic syndrome.
• hsCRP and homocysteine signal systemic inflammation that topical treatments won't address.
• Vitamin D, vitamin B12, and folate influence skin health, immune function, and melanocyte regulation.

Tracking these markers over time, not just reacting to individual flares, provides a clearer picture of what's driving melasma at a systemic level.

Getting to the Root of What's Driving Your Skin

Melasma isn't just about what you put on your skin. It's a signal from your hormones, your immune system, and your metabolic health. If your melasma keeps coming back despite doing everything right topically, Superpower's 100+ biomarker panel can show you what's happening beneath the surface. Hormones like estrogen, progesterone, and testosterone, inflammatory markers like hsCRP, thyroid function, insulin sensitivity, and nutrient levels all play a role in whether melasma appears, persists, or responds to treatment. Skin is one of the most visible signals your biology produces. Superpower's testing helps you read that signal at a systemic level, not just treat it at the surface.